Shopping Cart
- Remove All
Your shopping cart is currently empty
MK-0686
🥰Excellent
Catalog No. T33421Cas No. 578727-68-1
Alias MK0686
MK-0686 is an orally available bradykinin B1 receptor antagonist with potential anti-inflammatory activity.
MK-0686
🥰Excellent
Purity: 99.56%
Catalog No. T33421Alias MK0686Cas No. 578727-68-1
MK-0686 is an orally available bradykinin B1 receptor antagonist with potential anti-inflammatory activity.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $191 | In Stock | |
| 5 mg | $470 | In Stock | |
| 10 mg | $689 | In Stock | |
| 25 mg | $1,080 | In Stock | |
| 50 mg | $1,460 | In Stock | |
| 100 mg | $1,960 | In Stock | |
| 500 mg | $3,930 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "MK-0686"
5-Hydroxy-1-methylhydantoin
NZ-419, NZ419, NZ 419, HD-003, HD003, HD 003
T2822284210-26-4
5-Hydroxy-1-methylhydantoin (HD-003) is an antioxidant potentially for the treatment of renal failure. A creatinine metabolite, 5-Hydroxy-1-methylhydantoin , a hydroxyl radical scavenger, has previously been shown to confer renoprotection by inhibiting the progression of chronic kidney disease in rats. 5-Hydroxy-1-methylhydantoin is a novel anti-oxidant drug completely suppressed the expression of B2-kinin receptors (B2KR) in response to high glucose (25 mM) stimulation in VSMC and was also shown to attenuate the effects of BK on VSMC remodeling. 5-Hydroxy-1-methylhydantoin inhibited the BK-induced increase in MAPK phosphorylation and attenuated the increase in connective tissue growth factor (CTGF) protein levels in VSMC. These findings suggest that 5-Hydroxy-1-methylhydantoin may confer vascular protection against high glucose concentrations and BK-stimulation to ameliorate vascular injury and remodeling through its anti-oxidant properties.
- $30
Size
QTY
Safotibant
LF22-0542, LF-22-0542, LF-220542, LF220542, LF 22-0542, LF 220542
T34485633698-99-4In house
Safotibant (LF-22-0542) is a bradykinin B1 receptor antagonist with anti-inflammatory and analgesic activity for the topical treatment of diabetic macular edema.
- $146
Size
QTY
Anatibant 2HCl
Anatibant 2HCl(209733-45-9 Free base)
T26627L209788-45-4In house
Anatibant 2HCl is a small molecule bradykinin B2 receptor antagonist for the treatment of neurological disorders and may be used in the study of brain injury.
- $350
Size
QTY
ELN-441958
ELN 441958
T2086913064-47-8
ELN-441958 is a potent, neutral antagonist of the B1 receptor, inhibiting the binding of the B1 agonist ligand [3H]DAKD to IMR-90 cells with a Ki of 0.26 nM. ELN-441958 (ELN 441958) is highly selective for B1 over B2 receptors.
- $56
Size
QTY
Sar-[D-Phe8]-des-Arg9-Bradykinin acetate
Sar-[D-Phe8]-des-Arg9-Bradykinin acetate(126959-88-4 free base)
TP1917L1
Sar-[D-Phe8]-des-Arg9-Bradykinin acetate is a potent and selective bradykinin B1 receptor agonist (EC50 = 9.02 nM in rabbit aorta) that is resistant to aminopeptidase, kininase I and II (ACE) and neutral endopeptidase cleavage. Exhibits hypotensive and angiogenic activity in vivo.
- $185
Size
QTY
(Hyp³)-Bradykinin acetate
(Hyp³)-Bradykinin acetate (37642-65-2 Free base)
T36442L
(Hyp³)-Bradykinin acetate is an agonist of bradykinin B2 receptor and stimulates inositol phosphate production in cultured human fibroblasts.
- $79
Size
QTY
Lys-[Des-Arg9]Bradykinin acetate
Cited
Lys-[Des-Arg9]Bradykinin acetate (71800-36-7 free base)
TP1918L1
Lys-[Des-Arg9]Bradykinin acetate is an endogenous potent and highly selective bradykinin B1 receptor agonist (Ki values are 0.12 and > 30000 nM at human B1 and B2 receptors respectively). Hypotensive agent that reduces peripheral vascular resistance in vivo. 16-fold more potent than [Des-Arg9]-Bradykinin.
- $81
Size
QTY
CitedLys-Bradykinin acetate(342-10-9 free base)
TP2268L84640-50-6
Lys-Bradykinin acetate is an endogenous bradykinin receptor agonist.
- $98
Size
QTY
[Des-Arg9]-Bradykinin acetate
TP144523827-91-0
[Des-Arg9]-Bradykinin acetate is a selective agonist of the Bradykinin B1 receptor.
- $47
Size
QTY
NPC 567 acetate
NPC 567 acetate(109333-26-8 Free base)
T21060L
NPC 567 acetate is a bradykinin B2 antagonist and can be used in studies about the treatment of allergic airway disease.
- $195
Size
QTY
R715 TFA(185052-09-9 free base)
R 715
TP1933
R715 TFA(185052-09-9 free base) is a potent and selective bradykinin B1 receptor antagonist (pA2 = 8.49). Displays no activity at B2 receptors. Reduces mechanical hypernociception in a mouse model of neuropathic pain. Metabolically stable.
- $152
Size
QTY
Select Batch
Purity:99.56%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | MK-0686 is an orally available bradykinin B1 receptor antagonist with potential anti-inflammatory activity. |
| Alias | MK0686 |
| Molecular Weight | 486.84 |
| Formula | C22H19ClF4N2O4 |
| Cas No. | 578727-68-1 |
| Smiles | C(N[C@H](C)C1=C(F)C=C(C=C1)C2=C(C(OC)=O)C(Cl)=CC=C2)(=O)C3(NC(C(F)(F)F)=O)CC3 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (102.7 mM)  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy MK-0686 | purchase MK-0686 | MK-0686 cost | order MK-0686 | MK-0686 chemical structure | MK-0686 formula | MK-0686 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.